Every Form 4 that Lipocine Inc. (LPCN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow LPCN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LPCN filings page.
Lipocine Inc. (LPCN) director John W. Higuchi purchased 12,561 shares of common stock on September 28, 2026, at $2.16 per share; the transaction is described as a purchase in the open market or a private transaction. His directly held position after the purchase was 216,358 shares. No Rule 10b5-1 plan is reported.
Lipocine director Michael Grissinger received a grant of 2,000 stock options on August 3, 2026, each for Lipocine common stock at an exercise price of $2.11 per share and expiring on August 3, 2036. The options are subject to vesting: one-third of the shares vest on the one-year anniversary of August 3, 2027, and the remaining two-thirds vest monthly on a prorata basis over the following two years. The transaction was not reported as made under a Rule 10b5-1 trading plan.
Lipocine Inc. director and CEO Mahesh V. Patel received a new stock option grant as part of his compensation. He was awarded options to acquire 52,781 shares of Lipocine common stock at an exercise price of $2.49 per share, bringing his total stock option holdings reported in this filing to 227,214 options.
The grant is subject to vesting: one-third of the options will vest on June 29, 2027, and the remaining two-thirds will vest monthly on a prorated basis over the following two years. This structure is designed to tie his equity compensation to continued service and long-term performance.
Higuchi John W. reported acquisition or exercise transactions in this Form 4 filing.
Lipocine Inc. director John W. Higuchi received a grant of derivative securities giving him the right to buy 1,764 shares of common stock at $2.19 per share. These rights vest 100% one year from the grant date and expire on June 3, 2036. Following this award, Higuchi holds rights to purchase a total of 13,290 shares of common stock.
Lipocine Inc. director Jene Jill M. received a grant of stock options covering 1,764 shares of common stock at an exercise price of $2.19 per share. These options vest 100% one year from the grant date and expire on June 3, 2036. Following this grant, the director holds a total of 8,938 derivative securities directly.
Ono Richard Dana reported acquisition or exercise transactions in this Form 4 filing.
Lipocine Inc. director Richard Dana Ono received an equity award in the form of derivative rights to buy 1,764 shares of Common Stock at $2.19 per share. This grant is a compensation-related award, not an open-market purchase or sale. The rights vest 100% one year from the grant date and are exercisable until June 3, 2036. After this award, Ono holds derivative rights covering a total of 13,290 shares of Lipocine common stock directly.
Lipocine Inc. director John W. Higuchi increased his stake by purchasing 40,000 shares of common stock in an open-market transaction. He paid $2.03 per share, for a total of about $81,200. After this purchase, he directly holds 203,797 Lipocine shares.
Lipocine Inc. director John W. Higuchi reported an open-market purchase of company stock. On April 6, 2026, he bought 123,000 shares of Lipocine common stock at $2.05 per share, increasing his direct ownership to 163,797 shares after the transaction.
Lipocine Inc. director and Chief Executive Officer Mahesh V. Patel reported an open-market purchase of company stock. On this date, he bought 25,000 shares of Lipocine common stock at $2.03 per share. Following this transaction, he directly owns 160,679 common shares of Lipocine.
Lipocine Inc. Chief Executive Officer Mahesh V. Patel purchased 25,000 shares of Lipocine common stock in an open-market transaction at $2.02 per share on April 2, 2026. Following this trade, he directly owns 135,679 shares of Lipocine common stock.